$2.09 -$0.04 (-1.7%)

03:38 PM EDT on 06/20/19

ImmunoGen, Inc. (NASDAQ:IMGN)

CAPS Rating: 2 out of 5

The Company develops antibody-based anticancer therapeutics.

Current Price $2.09 Mkt Cap $314.0M
Open $2.15 P/E Ratio 0.00
Prev. Close $2.12 Div. (Yield) $0.00 (0.0%)
Daily Range $2.08 - $2.22 Volume 250,743
52-Wk Range $1.76 - $6.13 Avg. Daily Vol. 69


How do you think NASDAQ:IMGN will perform against the market?

Add Stock to CAPS Watchlist

All Players

311 Outperform
25 Underperform

All-Star Players

41 Outperform
4 Underperform

Wall Street

9 Outperform
0 Underperform

Top NASDAQ:IMGN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

infinitesimal (36.68)
Submitted June 06, 2015

After the disappointment with Phase3-Marianne trial in 1st line HER2neu positive breast cancer and drug Kadcyla, IMGN just showed at ASCO with their new experimental drug for platinum-resistant ovarian cancer that the idea of pairing an antibody with… More

zzlangerhans (99.78)
Submitted January 05, 2017

I didn't have time to write about ImmunoGen when I picked it to underperform at the end of October, but Seeking Alpha has given me plenty of motivation to write about it now. I was right about the pick when the stock dropped precipitously ahead of… More


Fools bullish on NASDAQ:IMGN are also bullish on:

Fools bearish on NASDAQ:IMGN are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about IMGN.


Member Avatar zzlangerhans (99.78) Submitted: 1/4/2017 10:25:42 PM : Underperform Start Price: $1.95 NASDAQ:IMGN Score: +30.23

I didn't have time to write about ImmunoGen when I picked it to underperform at the end of October, but Seeking Alpha has given me plenty of motivation to write about it now. I was right about the pick when the stock dropped precipitously ahead of the US presidential election, wrong after Trump won and the biotech sector roared back, right again in December, and now way wrong subsequent to the publication of the Seeking Alpha article on December 29.

The main premise of this entirely awful and empty article is that beaten down stocks get beaten down further in December due to tax loss selling and roar back in January due to the end of selling pressure and short covering. In reality, if any such rules were true then they would be immediately neutralized by traders playing the predictable pattern. One only has to look back a year to see the exact opposite occurring, where a weak end of 2015 was followed by an absolutely disastrous January and February 2016 for small cap biotech. The cited pattern simply doesn't exist.

The Seeking Alpha article claims that ImmunoGen is "neglected", but anyone who has followed developmental biotech for the last few years know that this statement is patently untrue. ImmunoGen has been a heavily followed and oft-hyped stock for many years, topping out close to 20 in mid 2015 based on optimism for their Roche-partnered ADC Kadcyla. Unfortunately, Kadcyla never sold as well as hoped and follow-on indications failed, so that it became clear that Kadcyla royalty revenues would never make ImmunoGen profitable. ImmunoGen has had to go back to the drawing board with antifolate mAb mirvetuximab for ovarian cancer, with a resultant huge increase in their quarterly burn. The real reason that ImmunoGen has lost 90% of its market cap isn't that the company is "neglected" or "overlooked" or "misunderstood". It is because the investment thesis that took the stock to 20 didn't pan out and the company is back to being a developmental biotech that is rapidly running out of a cash runway and has 100M in debt on its books.

The article rosily describes a cash position of 196M without mentioning that this number refers to the end of September, despite the article being written a full quarter later. The article also never mentions that the burn has been over 40M in recent quarters. Because the next quarterly numbers won't be issued until the annual report comes out in late February or early March, that gives traders an extra month to ignore reality and bid ImmunoGen up before the one-two punch of cash burns come then and in early May. Will mirvetuximab be ImmunoGen's salvation? Phase III data for ovarian cancer isn't expected until 2019. There may be some earlier stage data from combination trials in 2017, but this is of questionable significance. Endocyte also had an antifolate in phase III for ovarian cancer. How'd that work out for them?

Of course, the Seeking Alpha article doesn't address the scientific aspects of mirevetuximab at all. The author is content to rely on his thesis of December decline, January gain for a beaten down stock. Does the recent huge gain validate his thesis? Of course not. The upward trajectory began at the end of December, immediately after his article was published. This has nothing to do with tax loss selling or short covering and everything to do with momentum trading and algos. The only question is if the gains hold until the next earnings statement or if the momos bank their gains more quickly.


Member Avatar RowdyCat (73.41) Submitted: 8/9/2016 11:44:41 PM : Outperform Start Price: $3.08 NASDAQ:IMGN Score: -66.48

Strong pipeline, must have patience


Member Avatar foolandhuskerfan (< 20) Submitted: 7/14/2016 2:53:32 PM : Outperform Start Price: $2.81 NASDAQ:IMGN Score: -61.10

this will take off soon!


Find the members with the highest scoring picks in IMGN.

Score Leader


invest2success (94.99) Score: +371.98

The Score Leader is the player with the highest score across all their picks in IMGN.

Member Name Member
Call Time
Score Commentary
invest2success 94.99 3/12/2009 Underperform 3W $5.05 -58.02% +313.96% +371.98 0 Comment
anticitradeshort 31.82 4/20/2009 Underperform NS $7.73 -72.57% +248.93% +321.51 0 Comment
woNroFeybdooG 25.37 10/29/2009 Underperform 5Y $7.45 -71.54% +180.83% +252.37 0 Comment
anticitrademix < 20 11/2/2009 Underperform 5Y $6.70 -68.36% +183.68% +252.04 0 Comment
anticitrademix2 < 20 11/2/2009 Underperform 5Y $6.70 -68.36% +183.68% +252.04 0 Comment
longtermgrowth09 26.24 12/17/2009 Underperform 5Y $8.23 -74.24% +166.80% +241.04 0 Comment
striper56 72.10 12/1/2009 Underperform NS $7.84 -72.97% +165.19% +238.16 0 Comment
Korodas 69.91 9/1/2010 Underperform NS $5.50 -61.45% +172.74% +234.19 0 Comment
shorttest4 32.76 3/8/2010 Underperform 5Y $7.07 -70.01% +158.53% +228.55 0 Comment
haimp 26.58 10/7/2010 Underperform 5Y $6.73 -68.50% +154.98% +223.48 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Call Time
Score End Date Commentary
TrackUBS 91.47 9/27/2012 Underperform NS $15.27 -13.03% +34.60% +47.63 6/13/2014 @ $13.28 0 Comment
TrackCowenandCo 76.32 8/22/2012 Outperform NS $13.66 -84.48% +108.91% -193.39 0 Comment
TrackRothCapital 69.59 4/12/2012 Outperform NS $13.00 -83.69% +115.42% -199.11 0 Comment
TrackZacks < 20 9/23/2010 Underperform 3M $5.52 +103.80% +22.81% -80.99 11/9/2012 @ $11.25 1 Comment
TrackCanaccord 67.85 3/4/2010 Outperform NS $7.10 -70.14% +162.69% -232.84 0 Comment
TrackJimCramer 86.27 11/4/2009 Outperform 3W $6.72 -68.45% +181.55% -250.00 0 Comment
TrackBreanMurray 44.52 10/8/2009 Outperform NS $7.98 -73.43% +177.24% -250.67 0 Comment
TrackOppenheimer 20.94 7/7/2009 Outperform NS $8.77 +67.39% +67.04% +0.35 1/28/2013 @ $14.68 0 Comment
TrackMorganJos 72.36 8/4/2008 Outperform NS $4.98 -57.43% +141.74% -199.17 0 Comment
TrackRBCCapMkts 85.55 10/15/2007 Outperform NS $4.80 -55.83% +98.05% -153.89 0 Comment
TrackFerrisBaker < 20 10/4/2007 Outperform NS $4.52 +173.67% -10.25% +183.92 4/17/2012 @ $12.37 0 Comment
TrackEveillard 94.85 9/30/2007 Outperform NS $4.65 -54.41% +102.84% -157.25 1 Comment
TrackLazardCapit 52.21 5/30/2007 Outperform NS $5.75 +46.96% -41.72% +88.67 7/13/2009 @ $8.45 0 Comment
TrackCantorFitz 41.82 11/22/2006 Outperform NS $4.56 -53.84% +122.77% -176.61 0 Comment